Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates
Authors
Keywords
-
Journal
Applied Health Economics and Health Policy
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-08-07
DOI
10.1007/s40258-018-0419-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases
- (2018) Michael Schlander et al. VALUE IN HEALTH
- Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia
- (2017) Steven G. Morgan et al. HEALTH POLICY
- The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
- (2017) Alessandra Ferrario et al. PHARMACOECONOMICS
- The Early Awareness and Alert System in Sweden: History and Current Status
- (2017) Irene Eriksson et al. Frontiers in Pharmacology
- Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future
- (2017) Kim Pauwels et al. Frontiers in Pharmacology
- How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries
- (2017) Sabine Vogler et al. Applied Health Economics and Health Policy
- Policies for biosimilar uptake in Europe: An overview
- (2017) Evelien Moorkens et al. PLoS One
- Has The Era Of Slow Growth For Prescription Drug Spending Ended?
- (2016) Murray Aitken et al. HEALTH AFFAIRS
- Biosimilars: How Can Payers Get Long-Term Savings?
- (2016) Jorge Mestre-Ferrandiz et al. PHARMACOECONOMICS
- Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future
- (2016) Winnie de Bruijn et al. Frontiers in Pharmacology
- Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer
- (2016) Ana Clopes et al. JOURNAL OF MEDICAL ECONOMICS
- The End of the International Reference Pricing System?
- (2015) Ulf Persson et al. Applied Health Economics and Health Policy
- New Expensive Treatments for Hepatitis C Infection
- (2014) Troyen Brennan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Market access of cancer drugs in European countries: improving resource allocation
- (2013) Kim Pauwels et al. Targeted Oncology
- Forecasting drug utilization and expenditure in a metropolitan health region
- (2012) Björn Wettermark et al. BMC HEALTH SERVICES RESEARCH
- Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland
- (2012) Marion Bennie et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications
- (2012) Menno van Woerkom et al. Journal of Comparative Effectiveness Research
- Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers
- (2010) Jakub Adamski et al. BMC HEALTH SERVICES RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started